The incidence of a case of recurrent nephrolithiasis was 36 per 1,000 person-years in the SGLT-2 inhibitor group and 53 per 1,000 person-years in the GLP-1 receptor agonist group. The gene discussed is SLC5A2; the disease is nephrolithiasis.